Log in to save to my catalogue

An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo

An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3c17b40c03bf443c9109bfca507c868b

An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo

About this item

Full title

An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2023-07, Vol.14 (1), p.3959-3959, Article 3959

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Prophylactic vaccines for SARS-CoV-2 have lowered the incidence of severe COVID-19, but emergence of viral variants that are antigenically distinct from the vaccine strains are of concern and additional, broadly acting preventive approaches are desirable. Here, we report on a glycolipid termed 7DW8-5 that exploits the host innate immune system to e...

Alternative Titles

Full title

An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_3c17b40c03bf443c9109bfca507c868b

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3c17b40c03bf443c9109bfca507c868b

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-023-39738-1

How to access this item